中山醫學大學機構典藏 CSMUIR:Item 310902500/22207
English  |  正體中文  |  简体中文  |  全文笔数/总笔数 : 17918/22933 (78%)
造访人次 : 7425964      在线人数 : 272
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜寻范围 查询小技巧：
  • 您可在西文检索词汇前后加上"双引号"，以获取较精准的检索结果
  • 若欲以作者姓名搜寻，建议至进阶搜寻限定作者字段，可获得较完整数据
    •  进阶搜寻


    jsp.display-item.identifier=請使用永久網址來引用或連結此文件: https://ir.csmu.edu.tw:8080/ir/handle/310902500/22207


    题名: Echinocandins as alternative treatment for HIV-infected patients with Pneumocystis pneumonia
    作者: Yu-Shan Huang;Chun-Eng Liu;Shih-Ping Lin;Chen-Hsiang Lee;Chia-Jui Yang;Chi-Ying Lin;Hung-Jen Tang;Yi-Chien Lee;Yi-Chun Lin;Yuan-Ti Lee;Hsin-Yun Sun;Chien-Ching Hung;Taiwan HIV Study Group
    贡献者: 中山醫學大學;醫研所
    日期: 2019-07-01
    上传时间: 2022-03-29T03:55:01Z (UTC)
    出版者: Wolters Kluwer Health
    摘要: Objectives:
    Treatment with trimethoprim-sulfamethoxazole for Pneumocystis pneumonia (PCP) is often associated with adverse effects. Echinocandins, by inhibiting the cyst form of Pneumocystis jirovecii, may be an alternative therapy for PCP. However, clinical experience with echinocandins in the treatment of PCP remains limited among HIV-infected patients.

    Methods:
    From August 2013 to April 2018, data of HIV-infected patients with confirmed PCP who received echinocandins as alternative treatment because of intolerance or unresponsiveness to trimethoprim-sulfamethoxazole were retrospectively reviewed to assess the effectiveness and safety of echinocandins alone or in combination with other agents.

    Results:
    In total, 34 patients were included, with a median CD4+ count of 27 cells/μl [interquartile range (IQR), 20–93). Twenty-four patients (70.6%) presented with moderate-to-severe PCP. The most common adverse effects leading to withdrawal of trimethoprim-sulfamethoxazole were hepatotoxicity (29.4%), gastrointestinal upset (23.5%), and rash (17.6%). Nine patients (26.5%) were switched to echinocandins after failure of trimethoprim-sulfamethoxazole. The median interval before switch from trimethoprim-sulfamethoxazole to echinocandins was 9.0 days (IQR 5.0–14.0). The all-cause and PCP-related in-hospital mortality rate of patients receiving echinocandins as alternative therapy was 20.6% (7/34) and 14.7% (5/34), respectively. The all-cause in-hospital mortality was 0% in mild PCP cases and 29% (7/24) in moderate-to-severe PCP cases. Patients who had failed to respond to first-line trimethoprim-sulfamethoxazole treatment tended to have a higher in-hospital mortality rate than those without first-line trimethoprim-sulfamethoxazole failure (44.4% versus 12.0%, P = 0.06).

    Conclusion:
    Echinocandin therapy might serve as an alternative option for HIV-infected patients with PCP who are intolerable to trimethoprim-sulfamethoxazole.
    URI: https://ir.csmu.edu.tw:8080/handle/310902500/22207
    關聯: AIDS, 33(8), 1345-1351
    显示于类别:[醫學研究所] 期刊論文

    文件中的档案:

    档案 描述 大小格式浏览次数
    Echinocandins_as_alternative_treatment_for.8.pdf160KbAdobe PDF142检视/开启


    检视Licence

    SFX Query

    在CSMUIR中所有的数据项都受到原著作权保护.

    TAIR相关文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回馈